Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bleomycin exanthema].

H Lincke-Plewig

    Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
    |November 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Bleomycin treatment can cause skin rashes in patients. These cutaneous side effects typically emerge after 10-14 days of therapy, with cumulative doses ranging from 120-150 mg.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Comment on the contribution by J. Albig, H. Gollnick, U. Detmer and C. E. Orfanos. Flagella-like hyperpigmentation caused by bleomycin].

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·1993
    Same author

    [Spreading pigmented actinic keratosis--diagnosis and therapy].

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·1989
    Same author

    [Amelanotic malignant lentigo melanoma].

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·1986
    Same author

    [Lichenoid keratosis].

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·1982
    Same author

    [Histological differential diagnosis of psoriasis vulgaris and seborrheic eczema of the scalp].

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·1979
    Same author

    [Vitamins B6 and B12 in acne?].

    Deutsche medizinische Wochenschrift (1946)·1978
    Same journal

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
    Same journal

    [Viral infections of the skin].

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
    Same journal

    [Viral exanthems in children].

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
    Same journal

    [Erratum to: Digital health applications and data protection].

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
    Same journal

    [Virus-induced exanthems in returning travellers].

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
    Same journal

    [Venous ulcus cruris-Surgical treatment].

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
    See all related articles

    Area of Science:

    • Dermatology
    • Oncology
    • Pharmacology

    Context:

    • Bleomycin is an antineoplastic chemotherapy agent used in various cancers.
    • Cutaneous adverse events are known side effects of chemotherapy.
    • Monitoring for dermatological toxicity is crucial during bleomycin therapy.

    Purpose:

    • To report and characterize cutaneous side effects observed in patients treated with bleomycin.
    • To document the onset and dose-related incidence of bleomycin-induced rashes.

    Summary:

    • Four patients receiving bleomycin developed characteristic skin rashes.
    • The onset of these bleomycin rashes occurred between 10 to 14 days of treatment.
    • The observed cumulative bleomycin dose associated with rash development ranged from 120 to 150 mg.

    Related Experiment Videos

    Impact:

    • Highlights the potential for bleomycin to induce specific cutaneous reactions.
    • Informs clinicians about the typical timing and dosage for the emergence of bleomycin-related skin rashes.
    • Emphasizes the importance of dermatological surveillance in patients undergoing bleomycin chemotherapy.